539 related articles for article (PubMed ID: 25524478)
1. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A; Shirai K; Choi M; Laskin J; Kochenderfer M; Spira A; Cline-Burkhardt V; Winquist E; Hausman D; Walker L; Cohen RB
Ann Oncol; 2015 Mar; 26(3):556-61. PubMed ID: 25524478
[TBL] [Abstract][Full Text] [Related]
2. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A; Bauman JE; Weissman C; Adkins D; Schnadig I; Beauregard P; Bowles DW; Spira A; Levy B; Seetharamu N; Hausman D; Walker L; Rudin CM; Shirai K
Oral Oncol; 2015 Apr; 51(4):383-8. PubMed ID: 25593016
[TBL] [Abstract][Full Text] [Related]
3. A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Levy B; Spira A; Becker D; Evans T; Schnadig I; Camidge DR; Bauman JE; Hausman D; Walker L; Nemunaitis J; Rudin CM; Halmos B; Bowles DW
J Thorac Oncol; 2014 Jul; 9(7):1031-1035. PubMed ID: 24926548
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
Bowles DW; Kochenderfer M; Cohn A; Sideris L; Nguyen N; Cline-Burkhardt V; Schnadig I; Choi M; Nabell L; Chaudhry A; Ruxer R; Ucar A; Hausman D; Walker L; Spira A; Jimeno A
Clin Colorectal Cancer; 2016 Dec; 15(4):337-344.e2. PubMed ID: 27118441
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Kochanny SE; Worden FP; Adkins DR; Lim DW; Bauman JE; Wagner SA; Brisson RJ; Karrison TG; Stadler WM; Vokes EE; Seiwert TY
Cancer; 2020 May; 126(10):2146-2152. PubMed ID: 32073648
[TBL] [Abstract][Full Text] [Related]
6. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
Seiwert TY; Kochanny S; Wood K; Worden FP; Adkins D; Wade JL; Sleckman BG; Anderson D; Brisson RJ; Karrison T; Stadler WM; Vokes EE
Cancer; 2020 Jul; 126(14):3237-3243. PubMed ID: 32365226
[TBL] [Abstract][Full Text] [Related]
8. TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).
Grünwald V; Keilholz U; Boehm A; Guntinas-Lichius O; Hennemann B; Schmoll HJ; Ivanyi P; Abbas M; Lehmann U; Koch A; Karch A; Zörner A; Gauler TC
Ann Oncol; 2015 Mar; 26(3):561-7. PubMed ID: 25527417
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
Bowles DW; Senzer N; Hausman D; Peterson S; Vo A; Walker L; Cohen RB; Jimeno A
Invest New Drugs; 2014 Dec; 32(6):1197-203. PubMed ID: 24916771
[TBL] [Abstract][Full Text] [Related]
10. Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.
Guigay J; Le Caer H; Ferrand FR; Geoffrois L; Saada-Bouzid E; Fayette J; Sire C; Cupissol D; Blot E; Guillet P; Pavillet J; Bozec L; Capitain O; Rolland F; Debourdeau P; Pointreau Y; Falandry C; Lopez S; Coutte A; Chatellier T; Dalloz P; Ortholan C; Michel C; Lacas B; Cheurfa N; Schwob D; Bourhis J; Mertens C; Aupérin A;
Lancet Healthy Longev; 2024 Jun; 5(6):e392-e405. PubMed ID: 38759667
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Soulières D; Aguilar JL; Chen E; Misiukiewicz K; Ernst S; Lee HJ; Bryant K; He S; Obasaju CK; Chang SC; Chin S; Adkins D
BMC Cancer; 2016 Jan; 16():19. PubMed ID: 26768732
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.
Bauman JE; Saba NF; Roe D; Bauman JR; Kaczmar J; Bhatia A; Muzaffar J; Julian R; Wang S; Bearelly S; Baker A; Steuer C; Giri A; Burtness B; Centuori S; Caulin C; Klein R; Saboda K; Obara S; Chung CH
J Clin Oncol; 2023 Aug; 41(22):3851-3862. PubMed ID: 36977289
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
14. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Bossi P; Miceli R; Locati LD; Ferrari D; Vecchio S; Moretti G; Denaro N; Caponigro F; Airoldi M; Moro C; Vaccher E; Sponghini A; Caldara A; Rinaldi G; Ferrau F; Nolè F; Lo Vullo S; Tettamanzi F; Hollander L; Licitra L
Ann Oncol; 2017 Nov; 28(11):2820-2826. PubMed ID: 28950305
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
17. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
Geiger JL; Bauman JE; Gibson MK; Gooding WE; Varadarajan P; Kotsakis A; Martin D; Gutkind JS; Hedberg ML; Grandis JR; Argiris A
Head Neck; 2016 Dec; 38(12):1759-1764. PubMed ID: 27232378
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
Desilets A; Pfister DG; Stein S; Wong W; Sherman EJ; Fetten J; Hung TKW; Kriplani A; Dunn LA; Ho AL; Michel LS
Oral Oncol; 2024 Jul; 154():106861. PubMed ID: 38795600
[TBL] [Abstract][Full Text] [Related]
20. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
Keysar SB; Astling DP; Anderson RT; Vogler BW; Bowles DW; Morton JJ; Paylor JJ; Glogowska MJ; Le PN; Eagles-Soukup JR; Kako SL; Takimoto SM; Sehrt DB; Umpierrez A; Pittman MA; Macfadden SM; Helber RM; Peterson S; Hausman DF; Said S; Leem TH; Goddard JA; Arcaroli JJ; Messersmith WA; Robinson WA; Hirsch FR; Varella-Garcia M; Raben D; Wang XJ; Song JI; Tan AC; Jimeno A
Mol Oncol; 2013 Aug; 7(4):776-90. PubMed ID: 23607916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
